Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P M Stewart

Showing results (131-140 of 244) with videos related to

Pageof 25
Sort By:
Growth Hormone & IGF Research : Official Journal of the Growth Hormone Research Society and the International IGF Research Society|September 14, 2000
Thirty-day monitoring of insulin-like growth factors and their binding proteins in intensive care unit patientsR C Baxter, F H Hawker, C To, et al.
Clinical Endocrinology|December 1, 1992
Mineralocorticoid excess and inhibition of 11 beta-hydroxysteroid dehydrogenase in patients with ectopic ACTH syndromeB R Walker, J C Campbell, R Fraser, et al.
The American Journal of Physiology|June 1, 1993
11 beta-hydroxysteroid dehydrogenase and corticosteroid hormone receptors in the rat colonC B Whorwood, P C Barber, J Gregory, et al.
Clinical Endocrinology|July 1, 1987
Lithium inhibits the action of fludrocortisone on the kidneyP M Stewart, J Grieve, I M Nairn, et al.
The Journal of Biological Chemistry|April 11, 2001
Functional expression, characterization, and purification of the catalytic domain of human 11-beta -hydroxysteroid dehydrogenase type 1E A Walker, A M Clark, M Hewison, et al.
The Quarterly Journal of Medicine|August 1, 1993
Radioiodine therapy for hyperthyroidism in young patients--perception of risk and useM A Baxter, P M Stewart, J Daykin, et al.
Endocrinology|July 1, 1997
Differential expression of nuclear 11beta-hydroxysteroid dehydrogenase type 2 in mineralocorticoid receptor positive and negative tissuesM D Petrelli, S S Lim-Tio, J Condon, et al.
Clinical Endocrinology|May 14, 1998
Long-term therapy with long-acting octreotide (Sandostatin-LAR) for the management of acromegalyP H Davies, S E Stewart, L Lancranjan, et al.
Clinical Endocrinology|September 1, 1989
The kidney is the major site of cortisone production in manJ A Whitworth, P M Stewart, D Burt, et al.
The Journal of Clinical Endocrinology and Metabolism|February 1, 1995
Endogenous inhibitors of 11 beta-hydroxysteroid dehydrogenase in hypertensionB R Walker, I Aggarwal, P M Stewart, et al.
Pageof 25

Showing results (131-140 of 244) with videos related to

Sort By:
Pageof 25
Growth Hormone & IGF Research : Official Journal of the Growth Hormone Research Society and the International IGF Research Society|September 14, 2000
Thirty-day monitoring of insulin-like growth factors and their binding proteins in intensive care unit patientsR C Baxter, F H Hawker, C To, et al.
Clinical Endocrinology|December 1, 1992
Mineralocorticoid excess and inhibition of 11 beta-hydroxysteroid dehydrogenase in patients with ectopic ACTH syndromeB R Walker, J C Campbell, R Fraser, et al.
The American Journal of Physiology|June 1, 1993
11 beta-hydroxysteroid dehydrogenase and corticosteroid hormone receptors in the rat colonC B Whorwood, P C Barber, J Gregory, et al.
Clinical Endocrinology|July 1, 1987
Lithium inhibits the action of fludrocortisone on the kidneyP M Stewart, J Grieve, I M Nairn, et al.
The Journal of Biological Chemistry|April 11, 2001
Functional expression, characterization, and purification of the catalytic domain of human 11-beta -hydroxysteroid dehydrogenase type 1E A Walker, A M Clark, M Hewison, et al.
The Quarterly Journal of Medicine|August 1, 1993
Radioiodine therapy for hyperthyroidism in young patients--perception of risk and useM A Baxter, P M Stewart, J Daykin, et al.
Endocrinology|July 1, 1997
Differential expression of nuclear 11beta-hydroxysteroid dehydrogenase type 2 in mineralocorticoid receptor positive and negative tissuesM D Petrelli, S S Lim-Tio, J Condon, et al.
Clinical Endocrinology|May 14, 1998
Long-term therapy with long-acting octreotide (Sandostatin-LAR) for the management of acromegalyP H Davies, S E Stewart, L Lancranjan, et al.
Clinical Endocrinology|September 1, 1989
The kidney is the major site of cortisone production in manJ A Whitworth, P M Stewart, D Burt, et al.
The Journal of Clinical Endocrinology and Metabolism|February 1, 1995
Endogenous inhibitors of 11 beta-hydroxysteroid dehydrogenase in hypertensionB R Walker, I Aggarwal, P M Stewart, et al.
Pageof 25